A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
A Randomized, Double-masked, Comparative Clinical Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 938 8 mg Versus EYLEA® HD (Aflibercept) Delivered Via Intravitreal Injection in Participants With Neovascular Age-related Macular Degeneration
The aim of this trial is to demonstrate similarity in efficacy between ABP 938 8 mg and aflibercept (US) 8 mg by evaluating the change in best corrected visual acuity (BCVA) in participants with neovascular age-related macular degeneration (nAMD)
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 3단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Amgen Call Center
- 전화번호: 866-572-6436
- 이메일: medinfo@amgen.com
연구 장소
-
-
-
Riga, 라트비아, 1002
- 모병
- P.Stradina Clinical University Hospital - Ophthalmology
-
Riga, 라트비아, LV-1002
- 모병
- Riga East University Hospital - Department of Ophthalmology, Clinical Center "Bikernieki"
-
-
Riga
-
Riga, Riga, 라트비아, LV-1009
- 모병
- Latvian American Eye Center
-
-
-
-
Kaunas County
-
Kaunas, Kaunas County, 리투아니아, 50009
- 모병
- Lietuvos Sveikatos Mokslu Universitetas (LSMU) - Kauno Klinikos - ophthalmology
-
-
-
-
California
-
Fullerton, California, 미국, 92835-3432
- 모병
- Retina Consultants of Orange County
-
Long Beach, California, 미국, 90607
- 모병
- South Coast Retina Center - RCA
-
Modesto, California, 미국, 95356
- 모병
- Retinal Consultants Medical Group, Inc - Modesto (RCA)
-
Pasadena, California, 미국, 91107
- 모병
- California Eye Specialists Medical Group, Inc
-
Sacramento, California, 미국, 95825
- 모병
- Retinal Consultants Medical Group, Inc - Sacramento - Parkcenter Drive (RCA)
-
Santa Barbara, California, 미국, 93103
- 모병
- California Retina Consultants
-
-
Colorado
-
Colorado Springs, Colorado, 미국, 80909-1183
- 모병
- Retina Consultants of Southern Colorado (Colorado Springs)- RCA
-
Colorado Springs, Colorado, 미국, 80909
- 모병
- Retina Consultants of Southern Colorado (Pueblo)- RCA
-
Lakewood, Colorado, 미국, 80228
- 모병
- Colorado Retina Associates (RCA)
-
-
Connecticut
-
Waterford, Connecticut, 미국, 06385
- 모병
- Retina Group of New England
-
-
Florida
-
Miami, Florida, 미국, 33143
- 모병
- Medeye Associates - Research
-
Naples, Florida, 미국, 34103-4457
- 모병
- Retina Consultants of Southwest Florida - Naples
-
Pensacola, Florida, 미국, 32503
- 모병
- Advanced Research, LLC
-
-
Illinois
-
Chicago, Illinois, 미국, 60452
- 모병
- University Retina and Macula Associates, PC
-
Elmhurst, Illinois, 미국, 60126
- 모병
- Retina Associates
-
-
Indiana
-
Carmel, Indiana, 미국, 46032
- 모병
- Associated Vitreoretinal and Uveitis Consultants
-
-
Maryland
-
Baltimore, Maryland, 미국, 21209
- 모병
- The Retina Care Center- Baltimore (PRISM Vision Group)
-
Hagerstown, Maryland, 미국, 21740-5846
- 모병
- Mid Atlantic Retina Specialists
-
Towson, Maryland, 미국, 21204-6833
- 모병
- Retina Specialists
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02114
- 모병
- Ophthalmic Consultants of Boston
-
-
Minnesota
-
Edina, Minnesota, 미국, 55435
- 모병
- Retina Consultants of Minnesota (RCM) - St. Louis Park
-
-
Mississippi
-
Madison, Mississippi, 미국, 39110
- 모병
- Mississippi Retina Assoc
-
-
Missouri
-
St Louis, Missouri, 미국, 63128
- 모병
- The Retina Institute, Research Retina Institute (RCA)
-
-
New Jersey
-
Bloomfield, New Jersey, 미국, 07003
- 모병
- Envision Ocular, LLC
-
-
New Mexico
-
Albuquerque, New Mexico, 미국, 87109
- 모병
- Vision Research Center Eye Associates of New Mexico
-
-
New York
-
Liverpool, New York, 미국, 13088
- 모병
- Retina Vitreous Surgeons of CNY, PC
-
Oceanside, New York, 미국, 11572
- 모병
- Ophthalmic Consultants of Long Island - Research
-
Scarsdale, New York, 미국, 10583-5032
- 모병
- Long Island Vitreoretinal Consultants(RCA Network)
-
-
North Carolina
-
Raleigh, North Carolina, 미국, 27607-7514
- 모병
- North Carolina Retina Associates
-
Wake Forest, North Carolina, 미국, 27587
- 모병
- NC Retina Associates- RCA
-
-
Ohio
-
Dublin, Ohio, 미국, 43016
- 모병
- Midwest Retina - Main Office
-
-
Pennsylvania
-
Kingston, Pennsylvania, 미국, 18704-4801
- 모병
- Eye Care Specialists - Kingston
-
-
South Carolina
-
Beaufort, South Carolina, 미국, 29902
- 모병
- Retina Consultants of South Carolina, Charleston Neuroscience institute - Blufffon (RCA)
-
Charleston, South Carolina, 미국, 29414-5896
- 모병
- Charleston Neuroscience Institute
-
Columbia, South Carolina, 미국, 29169
- 모병
- Palmetto Retina Center - Main (RCA)
-
Ladson, South Carolina, 미국, 29456
- 모병
- Retina Consultants of South Carolina, Charleston Neuroscience Institute- Ladson (RCA)
-
Mt. Pleasant, South Carolina, 미국, 29464
- 모병
- Retina Consultants of South Carolina, Charleston Neuroscience Institute- Mount Pleasant (RCA)
-
West Columbia, South Carolina, 미국, 29169
- 모병
- Palmetto Retina Center, Florence (RCA)
-
-
Tennessee
-
Nashville, Tennessee, 미국, 37203
- 모병
- Tennessee Retina PC
-
-
Texas
-
Arlington, Texas, 미국, 76012
- 모병
- Texas Retina Associates (TRA) - Arlington
-
Austin, Texas, 미국, 78705
- 모병
- Austin Retina Associates
-
Austin, Texas, 미국, 78705
- 모병
- Austin Retina Associates - Ophthalmology/Retina
-
Bellaire, Texas, 미국, 77401
- 모병
- Retina Consultants of Texas - Bellaire
-
Dallas, Texas, 미국, 75231
- 모병
- Texas Retina Associates (TRA) - Dallas Main
-
Fort Worth, Texas, 미국, 76104
- 모병
- Texas Retina Associates - Fort Worth
-
Houston, Texas, 미국, 77401
- 모병
- Retina Consultants of Texas - Katy Retina Center
-
Katy, Texas, 미국, 77494
- 모병
- Retina Consultants of Texas - The Woodlands
-
San Antonio, Texas, 미국, 78240
- 모병
- Retinal Consultants of Texas- San Antonio
-
Schertz, Texas, 미국, 78154
- 모병
- Retina Consultants of Texas - Schertz
-
Willow Park, Texas, 미국, 76087
- 모병
- Strategic Clinical Research Group, LLC
-
-
Utah
-
Salt Lake City, Utah, 미국, 84107
- 모병
- Retina Associates of Utah - Retina Specialist
-
-
Virginia
-
Falls Church, Virginia, 미국, 22042-2349
- 모병
- Emerson Clinical Research- Virginia Retina Specialists
-
-
Washington
-
Bellevue, Washington, 미국, 98004-3779
- 모병
- Vitreoretinal Associates of Washington
-
Silverdale, Washington, 미국, 98383
- 모병
- Retina Center NW PLLC
-
Spokane, Washington, 미국, 99204-2509
- 모병
- Spokane Eye Clinic (OCT and optical exam
-
-
-
-
-
Madrid, 스페인, 28041
- 모병
- Hospital Universitario 12 de Octubre - Oftalmología
-
-
Barcelona
-
San Cugat Del Valles, Barcelona, 스페인, 08190
- 모병
- Hospital Universitari General de Catalunya
-
-
Catalonia
-
Barcelona, Catalonia, 스페인, 8021
- 모병
- Centro de Oftalmologia Barraquer (Barraquer Ophthalmology Centre)
-
-
Navarre
-
Navarra, Navarre, 스페인, 31008
- 모병
- Clinica Universidad de Navarra - Oftalmología
-
-
Sevilla
-
Santiago de Compostela, Sevilla, 스페인, 15706
- 모병
- Hospital Provincial De Conxo - Oftalmología
-
-
-
-
Bratislava Region
-
Bratislava, Bratislava Region, 슬로바키아, 851 07
- 모병
- Univerzitna nemocnica Bratislava - Ocna klinika SZU a UNB
-
Bratislava, Bratislava Region, 슬로바키아, 81108
- 모병
- Univerzitna nemocnica - Nemocnica svateho Michala, a.s. - Ocna ambulancia
-
Bratislava, Bratislava Region, 슬로바키아, 821 03
- 모병
- CMO Bratislava
-
Bratislava, Bratislava Region, 슬로바키아, 826 06
- 모병
- Univerzitna nemocnica Bratislava - Klin. oftalmologie LFUK a UNB
-
Bratislava, Bratislava Region, 슬로바키아, 851 07
- 모병
- Oftalmologicke centrum ProCare Betliarska
-
-
Košice Region
-
Trebišov, Košice Region, 슬로바키아, 075 01
- 모병
- NsP Trebisov, a.s. - Ocne oddelenie
-
-
Nitra Region
-
Nitra, Nitra Region, 슬로바키아, 950 01
- 모병
- Fakultna Nemocnica Nitra - Ocna Klinika
-
-
Trenčín Region
-
Banska Bystrica, Trenčín Region, 슬로바키아, 975 17
- 모병
- FNsP F.D.R. Banska Bystrica - II. Ocna klinika SZU
-
Trenčín, Trenčín Region, 슬로바키아, 911 71
- 모병
- Fakultna nemocnica Trencin - Ocna klinika
-
-
Žilina Region
-
Žilina, Žilina Region, 슬로바키아, 012 07
- 모병
- Fakultna nemocnica s poliklinikou Zilina - Ocne oddelenie
-
-
-
-
-
Fukushima, 일본, 9601295
- 모병
- Fukushima Medical University Hospital - Ophthalmology
-
Tokyo, 일본, 101-8309
- 모병
- Nihon University Hospital - Ophthalmology
-
-
Aichi-ken
-
Nagoya, Aichi-ken, 일본, 460-0008
- 모병
- SUGITA EYE HOSPITAL - Ophthalmology
-
-
Fukuoka
-
Fukuoka, Fukuoka, 일본, 812-0011
- 모병
- Hayashi Eye Hospital
-
-
Hyōgo
-
Amagasaki, Hyōgo, 일본, 660-8550
- 모병
- Hyogo Prefectural Amagasaki General Medical Center - Ophthalmology
-
-
Osaka
-
Tennoji-Ku, Osaka, 일본, 543-0001
- 모병
- University of the Ryukyus Hospital - Ophthalmology
-
-
Tokyo
-
Meguro-ku, Tokyo, 일본, 152-8902
- 모병
- Tokyo Medical Center - Ophthalmology
-
Sendai, Tokyo, 일본, 984-8560
- 모병
- Tokyo Medical University Hachioji Medical Center - Ophthalmology
-
-
Yamaguchi
-
Ube, Yamaguchi, 일본, 755-8505
- 모병
- Yamaguchi University Hospital
-
Ube, Yamaguchi, 일본, 7558505
- 모병
- Tokushima University Hospital - Ophthalmology
-
-
-
-
-
Prague, 체코, 100 34
- 모병
- FN Kralovske Vinohrady - Oftalmologicka klinika
-
-
Hradec Králové Region
-
Náchod, Hradec Králové Region, 체코, 547 01
- 모병
- Visus, spol. s r.o. - Nachod
-
-
Ostrava-město
-
Ostrava - Poruba, Ostrava-město, 체코, 708 52
- 모병
- Fakultni nemocnice Ostrava - Ocni klinika
-
-
Prague
-
Prague, Prague, 체코, 150 00
- 모병
- AXON clinical
-
Prague, Prague, 체코, 128 08
- 모병
- Vseobecna fakultni nemocnice v Praze - Ocni klinika
-
-
Stredoceský Kraj
-
Mladá Boleslav, Stredoceský Kraj, 체코, 293 01
- 모병
- Oblastni nemocnice Mlada Boleslav, a.s., nemocnice Stredoceskeho kraje - Klaudianova nemocnice
-
-
-
-
-
Bytom, 폴란드, 41-902
- 모병
- Caminomed Sp. z o.o.
-
-
Kuyavian-Pomeranian Voivodeship
-
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 폴란드, 85-631
- 모병
- OFTALMIKA Sp. z o. o.
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, 폴란드, 31-411
- 모병
- COMO Centrum Okulistyki Sp. z o.o.,
-
-
Lódzkie
-
Lodz, Lódzkie, 폴란드, 90-302
- 모병
- Santa Familia PTG Lodz
-
-
Masovian Voivodeship
-
Krakow, Masovian Voivodeship, 폴란드, 30-363
- 모병
- Szpital sw. Rozy Sp. z o.o.
-
-
Pomeranian Voivodeship
-
Warszawa, Pomeranian Voivodeship, 폴란드, 01-258
- 모병
- Warszawski Szpital Okulistyczny
-
-
Warmian-Masurian Voivodeship
-
Olsztyn, Warmian-Masurian Voivodeship, 폴란드, 10-424
- 모병
- Centrum Diagnostyki i Mikrochirurgii Oka-Lens Sp. z o.o.
-
-
-
-
-
Budapest, 헝가리, H-1062
- 모병
- Eszak-pesti Centrumkorhaz - Honvedkorhaz
-
-
Baranya Varmegye
-
Dombóvár, Baranya Varmegye, 헝가리, 7621
- 모병
- Ganglion Orvosi Kozpont - Nozologen Kft - Szemeszet
-
-
Csongrad-Csanad Varmegye
-
Szeged, Csongrad-Csanad Varmegye, 헝가리, 6720
- 모병
- Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont Szemeszeti Klinika
-
-
Hajdú-Bihar
-
Debrecen, Hajdú-Bihar, 헝가리, 4032
- 모병
- Debreceni Egyetem OEC - Ophthalmology
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Men or women ≥ 50 years old, capable of giving signed informed consent
- Active, treatment-naïve subfoveal CNV lesions secondary to nAMD including juxtafoveal lesions that affect the fovea as confirmed by SD-OCT and FA in the study eye (SE)
- Total area of CNV (including both classic and occult components) > 50% of the total lesion area in the SE
- The BCVA letter score ≥ 24 and ≤ 78 letters, in the SE
- Presence of intra and/or subretinal fluid affecting the central subfield of the SE as identified by SD-OCT attributable to active CNV. The central subfield is defined as a circle with a diameter of 1 mm, centered on the fovea
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply at either screening or baseline, unless otherwise indicated per protocol:
- Total lesion size > 12 disc areas (30.5 mm2) including blood, scars, and neovascularization, in the study eye
- Scar, fibrosis, or atrophy involving the central subfield in the study eye
- Scar or fibrosis involving > 50% of the total lesion in the study eye
- Presence of retinal pigment epithelium tears or rips involving the macula in the study eye
- History of any vitreous hemorrhage ≤ 4 weeks (28 days) before randomization in the study
- Presence of other causes of CNV, including pathologic myopia (spherical equivalent ≥ 8 diopters negative or axial length ≥ 25 mm), ocular histoplasmosis syndrome, angioid streaks, choroidal rupture, or multifocal choroiditis in the study
- Uncontrolled glaucoma (defined as IOP >25 mmHg despite treatment with anti-glaucoma medication) in the study eye
- History or clinical evidence of DR, DME, idiopathic autoimmune uveitis, or any other vascular disease affecting the retina, other than nAMD in either eye
- Evidence of active extraocular or periocular infection or inflammation (including infectious blepharitis, keratitis, scleritis, or conjunctivitis) in either eye at the time of screening or randomization
- Uncontrolled blood pressure (defined as systolic >160 mmHg or diastolic >95 mmHg). Blood pressure needs to be stable for at least 12 weeks (84 days) prior to screening
- Any prior or concomitant ocular or systemic treatment (with an investigational or approved, anti VEGF or anti-VEGF/anti-angiopoietin agent) in the SE, or surgery for nAMD in the SE, except dietary supplements or vitamins
- History or evidence of any other clinically significant disorder, condition, disease or clinical laboratory abnormality that, in the opinion of the investigator or study medical monitor, if consulted, would pose a risk to participant safety or interfere with the study evaluation or results interpretation
- Other protocol-specified exclusion criteria
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: ABP 938 8 mg
Participants will receive intravitreal ABP 938 8 mg injections at Baseline, Week 4, and Week 8. Participants will then be assessed at scheduled study visits, with Dose Regimen Adjustment (DRA) decisions beginning at Week 16 based on predefined disease-activity criteria. Injections will be administered at protocol-defined intervals ranging from every 4 to 16 weeks through the end of the study. |
IVT injection |
|
활성 비교기: Aflibercept (US) 8 mg
Participants will receive intravitreal Aflibercept (US) 8 mg injections at Baseline, Week 4, and Week 8. Participants will then be assessed at scheduled study visits, with DRA decisions beginning at Week 16 based on predefined disease-activity criteria. Injections will be administered at protocol-defined intervals ranging from every 4 to 16 weeks through the end of the study. |
IVT injection
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Change From Baseline in BCVA as measured by Early Treatment Diabetic Retinopathy Study (ETDRS) letter score
기간: Baseline and Week 12
|
Baseline and Week 12
|
2차 결과 측정
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
Percentage of Participants With Absence of Intraretinal Fluid (IRF) and Subretinal Fluid (SRF) in the Center Subfield, as Assessed by Spectral-Domain Optical Coherence Tomography (SD-OCT)
기간: Week 16
|
Week 16
|
|
Change from Baseline in BCVA as measured by ETDRS letter score
기간: Baseline to Week 48
|
Baseline to Week 48
|
|
Percentage of Participants Who Gained at Least 15 Letters of Vision From Baseline to Week 24
기간: Baseline to Week 24
|
Baseline to Week 24
|
|
Percentage of Participants Who Gained at Least 15 Letters of Vision From Baseline to Week 48
기간: Baseline to Week 48
|
Baseline to Week 48
|
|
Change From Baseline in Choroidal Neovascularization (CNV) Area Size as Measured by Fluorescein Angiography (FA)
기간: Baseline to Week 48
|
Baseline to Week 48
|
|
Change From Baseline in Central Subfield Thickness (CST) as Measured by SD-OCT
기간: Baseline to Week 48
|
Baseline to Week 48
|
|
Percentage of Participants Who Met Protocol-Defined DRA Criteria, as Determined by Protocol-Specified Clinical and Imaging Assessments
기간: Week 16 and Week 20
|
Week 16 and Week 20
|
|
Percentage of Participants Who Met Protocol-Defined DRA Criteria, as Determined by Protocol-Specified Clinical and Imaging Assessments
기간: Week 48
|
Week 48
|
|
Number of Participants Who Experienced Ocular Treatment-Emergent Adverse Events (TEAEs)
기간: Baseline up to Week 48
|
Baseline up to Week 48
|
|
Number of Participants Who Experienced Non-Ocular TEAEs
기간: Baseline up to Week 48
|
Baseline up to Week 48
|
|
Number of Participants Who Experienced Treatment-Emergent Events of Interest (EOI)
기간: Baseline up to Week 48
|
Baseline up to Week 48
|
|
Number of Participants Who Experienced Treatment-Emergent Serious Adverse Events (TESAEs)
기간: Baseline up to Week 48
|
Baseline up to Week 48
|
|
Number of Participants Who Developed Binding Antidrug Antibodies (ADAs)
기간: Baseline up to Week 48
|
Baseline up to Week 48
|
|
Free serum concentrations of ABP 938 8 mg
기간: Week 16, week 24 and 48 (End of Study)
|
Week 16, week 24 and 48 (End of Study)
|
|
Free serum concentrations of Aflibercept (US) 8 mg
기간: Week 16, week 24, and 48 (End of Study)
|
Week 16, week 24, and 48 (End of Study)
|
|
Pharmacokinetic (PK) parameters of ABP 938 8mg derived from concentration - time profiles following the first dose in a PK substudy
기간: From Baseline (day 1, week 0) to Day 29 (pre dose week 4)
|
From Baseline (day 1, week 0) to Day 29 (pre dose week 4)
|
|
Pharmacokinetic parameters of Aflibercept (US) 8 mg derived from concentration - time profiles following the first dose in a PK substudy
기간: From Baseline (day 1, week 0) to Day 29 (pre dose week 4)
|
From Baseline (day 1, week 0) to Day 29 (pre dose week 4)
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: MD, Amgen
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- 20250115
- 2025-523500-72-00 (씨티스)
- 2025 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
IPD 공유 기간
Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
IPD 공유 액세스 기준
Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
- ICF
- CSR
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .